Twenty-six triazole-based derivatives were designed for targeting both PD-L1 (programmed death receptor ligand 1) and VEGFR-2 (vascular endothelial growth factor receptor 2). These compounds were synthetized and biologically evaluated as multitarget inhibitors of VEGFR-2, PD-L1 and c-Myc proteins. The antiproliferative activity of these molecules on several tumor cell lines (HT-29, A-549, and MCF-7) and on the non-tumor cell line HEK-293 was determined. The effects on the abovementioned biological targets were evaluated for some selected compounds. Compound , bearing a -chlorophenyl group, showed better results than sorafenib in regard to the downregulation of VEGFR-2 and a similar effect to BMS-8 on both PD-L1 and c-Myc proteins. The antiangiogenic and antivascular activities of chloro derivatives were also established by endothelial microtube formation assay on Matrigel.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266368PMC
http://dx.doi.org/10.3390/ijms23137049DOI Listing

Publication Analysis

Top Keywords

pd-l1 c-myc
8
c-myc proteins
8
synthesis biological
4
biological evaluation
4
evaluation small
4
small molecules
4
molecules potential
4
potential anticancer
4
anticancer multitarget
4
multitarget agents
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!